Recent News
Powered by Alpha Vantage
No recent news found.
AI Tools
Key Metrics
Trend: Range-Bound
As of 2025-09-10 (Snapshot)
Arrowhead Pharmaceuticals, Inc. develops drugs for the treatment of intractable diseases in the United States. The company is headquartered in Pasadena, California.
52W High
$29.34
52W Low
$9.57
MA Status:
50D: Above
200D: Above
Beta (~1 neutral, <0.9 lower risk)
1.01
Valuation
Rich
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
111.11
EV/EBITDA (<8 favorable)
-11.02
EV/Revenue (<3 favorable)
6.06
P/S (TTM) (<3 favorable)
7.02
P/B (<3 favorable)
7.70
Ownership
Institution‑heavySource: Overview
Insiders (1–5% typical)
4.43%
Institutions (25–75% balanced)
77.51%
Shares Outstanding
138,258,000
Float
118,913,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
572,976,000
Gross Profit (TTM)
572,976,000
EPS (TTM)
-1.20
Profit Margin (>10% good)
-0.26%
Operating Margin (TTM) (higher better)
-5.96%
ROE (TTM) (>15% strong)
-0.37%
EPS YoY (Quarterly) (>10% good)
0.10
Revenue YoY (Quarterly) (>8% good)
-0.30
Momentum
Bearish momentumValue
3.5490
Previous
3.5040
Trend
Rising
Signal Cross
No cross
As of
Sep. 12, 2025